Market Overview:
The global MRD testing market is expected to grow at a CAGR of 10.8% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of cancer, technological advancements in MRD testing methods, and rising demand for personalized medicine. The global MRD testing market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into flow cytometry, polymerase chain reaction (PCR), and next-generation sequencing (NGS). Flow cytometry held a dominant share in 2017 owing to its high accuracy and sensitivity. However, NGS is expected to grow at a higher CAGR during the forecast period as it offers several advantages over other methods such as faster turnaround time and lower cost per sample analyzed. On the basis of application, the global MRD testing market is segmented into specialty clinics and hospitals; diagnostic laboratories; research institutions; pharmaceutical companies; contract research organizations (CROs); biotechnology companies; academic institutes/universities; government agencies/regulatory bodies; patient advocacy groups/nonprofit organizations ;and others including molecular pathology labs,. Specialty clinics held a dominant share in 2017 owing to rising demand for personalized medicine across all regions. However ,research institutions are expected to grow at highest CAGR during 2018-2030 due its growing use for drug discovery & development purposes .
 Testing Industry Outlook.svg)
Product Definition:
MRD (minimal residual disease) testing is a way to measure how much cancer remains in the body after treatment. This information can help doctors decide if more treatment is needed.
Flow Cytometry:
Flow cytometry is a technique that measures cell properties and characteristics such as size, shape, and granularity. It also determines the percentage of each type of cell in the population. Flow cytometry has been used for decades to study cellular heterogeneity in diseases and healthy tissues by determining normal as well as abnormal cells within them.
Polymerase Chain Reaction (PCR):
Polymerase chain reaction (PCR) is a technique that involves the amplification of specific DNA or RNA sequences in a targeted region. The method is widely used for the diagnosis of genetic disorders, such as cancer and infections. In molecular diagnostics, PCR is used to detect and measure minimal residual disease (MRD) in patients with breast cancer.
Application Insights:
Specialty clinics and hospitals held the largest share of over 70.0% in 2017. The key factor contributing to the large share of this segment is that these institutions have a high volume of testing activities, which include molecular diagnostic tests for various cancers and other infectious diseases. These specialty clinics and hospitals are also equipped with advanced technologies such as immunoassays, polymerase chain reaction (PCR), Southern Blotting, western blotting, ELISA etc., which enables them to carry out sensitive diagnosis with higher accuracy levels than general laboratories.
The diagnostics laboratories segment is expected to register the fastest growth during forecast years owing to an increase in demand for rapid diagnosis of minimal residual disease (MRD) among patients suffering from chronic myelogenous leukemia (CML). In addition, increasing R&D investments by pharmaceutical companies for developing novel diagnostic techniques will boost market growth during this period.
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to the presence of key players, high adoption rate of advanced technologies and increasing focus on drug development. Moreover, rising incidence of cancer is one major factor responsible for the growth in this region. According to a recent study published by American Cancer Society, Inc., around 1,762,780 new cases were estimated to be diagnosed in 2019 in North America and about 600 deaths were predicted to occur due to it.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing its large population base suffering from chronic diseases such as cancer and infectious disorders that need treatment with drugs that require MRD testing before launch into clinical trials. In addition there has been an increase in government initiatives aimed at accelerating drug development programs through clinical trials conducted among patients living outside U.S.
Growth Factors:
- Increasing incidence of cancer: The increasing incidence of cancer is the major growth driver for MRD testing market. According to the World Health Organization (WHO), an estimated 14 million new cases of cancer were diagnosed in 2012 and this number is expected to rise to 24 million by 2030. This will create a large pool of patients who will require MRD testing for effective treatment.
- Growing demand for personalized medicine: The growing demand for personalized medicine is another key growth driver for MRD testing market. With the advent of next-generation sequencing technologies, it has become possible to identify genetic mutations that are associated with specific cancers and thus, tailor treatment accordingly. This trend is likely to fuel the demand for MRD testing in the coming years.
- Rising awareness about early detection: There is a growing awareness among people about the importance of early detection in improving survival rates from cancer diseases .This is driving them towards seeking timely diagnosis and appropriate treatment, which in turn is fueling the demand for MRD tests .
Scope Of The Report
Report Attributes
Report Details
Report Title
MRD (Minimal Residual Disease) Testing Market Research Report
By Type
Flow Cytometry, Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS)
By Application
Specialty Clinics and Hospitals, Diagnostic Laboratories, Research Institutions
By Companies
ICON plc, ArcherDX(Invitae), ARUP Laboratories, Asuragen, Cergentis B.V., Bio-Rad Laboratories, Mission Bio, Guardant Health, Invivoscribe, LabCorp, Inivata, Natera, NeoGenomics Laboratories, Opko Health, Quest Diagnostics, Sysmex Corporation, Adaptive Biotechnologies
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
239
Number of Tables & Figures
168
Customization Available
Yes, the report can be customized as per your need.
Global MRD (Minimal Residual Disease) Testing Market Report Segments:
The global MRD (Minimal Residual Disease) Testing market is segmented on the basis of:
Types
Flow Cytometry, Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS)
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Specialty Clinics and Hospitals, Diagnostic Laboratories, Research Institutions
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- ICON plc
- ArcherDX(Invitae)
- ARUP Laboratories
- Asuragen
- Cergentis B.V.
- Bio-Rad Laboratories
- Mission Bio
- Guardant Health
- Invivoscribe
- LabCorp
- Inivata
- Natera
- NeoGenomics Laboratories
- Opko Health
- Quest Diagnostics
- Sysmex Corporation
- Adaptive Biotechnologies
 Testing Market Overview.svg)
Highlights of The MRD (Minimal Residual Disease) Testing Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Flow Cytometry
- Polymerase Chain Reaction (PCR)
- Next-Generation Sequencing (NGS)
- By Application:
- Specialty Clinics and Hospitals
- Diagnostic Laboratories
- Research Institutions
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the MRD (Minimal Residual Disease) Testing Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
 Testing Market Statistics.svg)
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
MRD testing is a blood test that measures the amount of cancer cells in a person's blood. It can help doctors determine whether the person has cancer and how large it is. MRD testing is also used to monitor treatment for cancer.
Some of the major companies in the mrd (minimal residual disease) testing market are ICON plc, ArcherDX(Invitae), ARUP Laboratories, Asuragen, Cergentis B.V., Bio-Rad Laboratories, Mission Bio, Guardant Health, Invivoscribe, LabCorp, Inivata, Natera, NeoGenomics Laboratories, Opko Health, Quest Diagnostics, Sysmex Corporation, Adaptive Biotechnologies.
The mrd (minimal residual disease) testing market is expected to register a CAGR of 10.8%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 MRD (Minimal Residual Disease) Testing Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 MRD (Minimal Residual Disease) Testing Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 MRD (Minimal Residual Disease) Testing Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the MRD (Minimal Residual Disease) Testing Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global MRD (Minimal Residual Disease) Testing Market Size & Forecast, 2018-2028
4.5.1 MRD (Minimal Residual Disease) Testing Market Size and Y-o-Y Growth
4.5.2 MRD (Minimal Residual Disease) Testing Market Absolute $ Opportunity
Chapter 5 Global MRD (Minimal Residual Disease) Testing Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 MRD (Minimal Residual Disease) Testing Market Size Forecast by Type
5.2.1 Flow Cytometry
5.2.2 Polymerase Chain Reaction (PCR)
5.2.3 Next-Generation Sequencing (NGS)
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global MRD (Minimal Residual Disease) Testing Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 MRD (Minimal Residual Disease) Testing Market Size Forecast by Applications
6.2.1 Specialty Clinics and Hospitals
6.2.2 Diagnostic Laboratories
6.2.3 Research Institutions
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global MRD (Minimal Residual Disease) Testing Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 MRD (Minimal Residual Disease) Testing Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America MRD (Minimal Residual Disease) Testing Analysis and Forecast
9.1 Introduction
9.2 North America MRD (Minimal Residual Disease) Testing Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America MRD (Minimal Residual Disease) Testing Market Size Forecast by Type
9.6.1 Flow Cytometry
9.6.2 Polymerase Chain Reaction (PCR)
9.6.3 Next-Generation Sequencing (NGS)
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America MRD (Minimal Residual Disease) Testing Market Size Forecast by Applications
9.10.1 Specialty Clinics and Hospitals
9.10.2 Diagnostic Laboratories
9.10.3 Research Institutions
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe MRD (Minimal Residual Disease) Testing Analysis and Forecast
10.1 Introduction
10.2 Europe MRD (Minimal Residual Disease) Testing Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe MRD (Minimal Residual Disease) Testing Market Size Forecast by Type
10.6.1 Flow Cytometry
10.6.2 Polymerase Chain Reaction (PCR)
10.6.3 Next-Generation Sequencing (NGS)
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe MRD (Minimal Residual Disease) Testing Market Size Forecast by Applications
10.10.1 Specialty Clinics and Hospitals
10.10.2 Diagnostic Laboratories
10.10.3 Research Institutions
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific MRD (Minimal Residual Disease) Testing Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific MRD (Minimal Residual Disease) Testing Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific MRD (Minimal Residual Disease) Testing Market Size Forecast by Type
11.6.1 Flow Cytometry
11.6.2 Polymerase Chain Reaction (PCR)
11.6.3 Next-Generation Sequencing (NGS)
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific MRD (Minimal Residual Disease) Testing Market Size Forecast by Applications
11.10.1 Specialty Clinics and Hospitals
11.10.2 Diagnostic Laboratories
11.10.3 Research Institutions
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America MRD (Minimal Residual Disease) Testing Analysis and Forecast
12.1 Introduction
12.2 Latin America MRD (Minimal Residual Disease) Testing Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America MRD (Minimal Residual Disease) Testing Market Size Forecast by Type
12.6.1 Flow Cytometry
12.6.2 Polymerase Chain Reaction (PCR)
12.6.3 Next-Generation Sequencing (NGS)
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America MRD (Minimal Residual Disease) Testing Market Size Forecast by Applications
12.10.1 Specialty Clinics and Hospitals
12.10.2 Diagnostic Laboratories
12.10.3 Research Institutions
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) MRD (Minimal Residual Disease) Testing Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) MRD (Minimal Residual Disease) Testing Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) MRD (Minimal Residual Disease) Testing Market Size Forecast by Type
13.6.1 Flow Cytometry
13.6.2 Polymerase Chain Reaction (PCR)
13.6.3 Next-Generation Sequencing (NGS)
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) MRD (Minimal Residual Disease) Testing Market Size Forecast by Applications
13.10.1 Specialty Clinics and Hospitals
13.10.2 Diagnostic Laboratories
13.10.3 Research Institutions
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 MRD (Minimal Residual Disease) Testing Market: Competitive Dashboard
14.2 Global MRD (Minimal Residual Disease) Testing Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 ICON plc
14.3.2 ArcherDX(Invitae)
14.3.3 ARUP Laboratories
14.3.4 Asuragen
14.3.5 Cergentis B.V.
14.3.6 Bio-Rad Laboratories
14.3.7 Mission Bio
14.3.8 Guardant Health
14.3.9 Invivoscribe
14.3.10 LabCorp
14.3.11 Inivata
14.3.12 Natera
14.3.13 NeoGenomics Laboratories
14.3.14 Opko Health
14.3.15 Quest Diagnostics
14.3.16 Sysmex Corporation
14.3.17 Adaptive Biotechnologies
